<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152004</url>
  </required_header>
  <id_info>
    <org_study_id>201800871A3</org_study_id>
    <nct_id>NCT05152004</nct_id>
  </id_info>
  <brief_title>Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment - a Randomized Trial</brief_title>
  <official_title>Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment - a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a&#xD;
      high eradication rate for clarithromycin-resistant strains, and have a great potential to&#xD;
      replace bismuth quadruple therapy in the treatment of H. pylori infection. This study aims to&#xD;
      better understand the potential of both hybrid and igh-dose dual therapies in the treatment&#xD;
      of H. pylori infection.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori (H. pylori) infect more than 50% of humans globally. It is the principal&#xD;
      cause of chronic gastritis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma and gastric&#xD;
      mucosa-associated lymphoid tissue lymphoma (MALToma). The Real-world Practice &amp; Expectation&#xD;
      of Asia-Pacific Physicians and Patients in H. pylori Eradication (REAP-HP) Survey&#xD;
      demonstrated that standard triple therapy was still the most commonly used anti-H. pylori&#xD;
      regimen in the Asia Pacific region. However, the eradication rates of standard triple therapy&#xD;
      have declined to less than 80% in most countries worldwide. The main reasons for eradication&#xD;
      failure of standard triple therapy include antibiotic resistance, poor compliance and CYP2C19&#xD;
      genotype of host. Clarithromycin resistance of H. pylori has been identified as the main&#xD;
      reason for the failure of standard triple therapy. Pooled data from 20 studies involving&#xD;
      1,975 patients treated with standard triple therapy showed an eradication rate of 88% in&#xD;
      clarithromycin-sensitive strains versus 18% in clarithromycin-resistant strains. Therefore,&#xD;
      the background rate of clarithromycin resistance is critically important for the efficacy of&#xD;
      standard triple therapy. Recently, several strategies including bismuth-containing quadruple&#xD;
      therapy, non-bismuth quadruple therapy (i.e., sequential therapy, concomitant therapy and&#xD;
      hybrid therapy) and high-dose dual therapy have been proposed to increase the eradication&#xD;
      rate.&#xD;
&#xD;
      Hybrid therapy developed by our study group in 2011 consists of a dual therapy with a proton&#xD;
      pump inhibitor (PPI) and amoxicillin for 7 days followed by a quadruple regimen with a PPI,&#xD;
      amoxicillin, clarithromycin and metronidazole for 7 days [10]. It achieved an eradication&#xD;
      rate of 97.4% by intention-to-treat (ITT) analysis and 99.1% by per-protocol (PP) analysis in&#xD;
      a Taiwan population with clarithromycin resistance rate of 7%. Subsequent randomized&#xD;
      controlled trials demonstrated that 14-day hybrid therapies were comparable or more effective&#xD;
      than 10-day sequential therapies. A recent large multicentre randomized controlled trial&#xD;
      documented that 14-day hybrid and 14-day concomitant therapies had comparable efficacy in the&#xD;
      treatment of H. pylori infection, and both could cure more than 90% of patients with H.&#xD;
      pylori infections in areas of high clarithromycin and metronidazole resistance [24].&#xD;
      Therefore, hybrid therapy has a great potential to replace bismuth quadruple therapy in the&#xD;
      first-line treatment of H. pylori infection. Currently, hybrid therapy is a recommended&#xD;
      first-line treatment for H. pylori infection in the ACG guideline&#xD;
&#xD;
      , Bangkok Consensus Report and Taiwan Consensus Report. High-dose dual therapy developed by&#xD;
      Yang et al. is another emerging treatment for H pylori infection. The new therapy consists of&#xD;
      high-dose PPI and amoxicillin, which keep the intragastric pH at a value higher than 6.5&#xD;
      regardless of CYP2C19 genotype and maintain steady plasma concentration of amoxicillin above&#xD;
      the minimal inhibitory concentration (MIC) for H pylori [28]. The efficacy of the new therapy&#xD;
      was significantly higher than that of standard triple therapy in Taiwan. However, it was less&#xD;
      effective as the first-line therapy for eradicating H pylori in Korea and in the United&#xD;
      States.&#xD;
&#xD;
      This study aims to better understand the potential of both hybrid and igh-dose dual therapies&#xD;
      in the treatment of H. pylori infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional Study Model</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rates of H.pylori eradication</measure>
    <time_frame>4-8 weeks</time_frame>
    <description>The primary outcome variables were the rates of eradication. Chi-square test with or without Yates correction for continuity and Fisher's exact test were used when appropriate to compare the major outcomes between groups. A P value less than 0.05 was considered statistically significant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>High dose dual therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 750 mg q.i.d for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hybrid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 1 g b.i.d. for 7 days, followed by rabeprazole (Pariet) 20 mg, amoxicillin(Amolin)1 g, clarithromycin (Klaricid) 500 mg, and metronidazole (Flagyl) 500 mg b.i.d. for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pariet</intervention_name>
    <description>Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days</description>
    <arm_group_label>High dose dual therapy</arm_group_label>
    <arm_group_label>Hybrid therapy</arm_group_label>
    <other_name>Rabeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amolin</intervention_name>
    <description>Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days</description>
    <arm_group_label>High dose dual therapy</arm_group_label>
    <arm_group_label>Hybrid therapy</arm_group_label>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Klaricid</intervention_name>
    <description>Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days</description>
    <arm_group_label>Hybrid therapy</arm_group_label>
    <other_name>Clarithromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flagyl</intervention_name>
    <description>Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days</description>
    <arm_group_label>Hybrid therapy</arm_group_label>
    <other_name>Metronidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. H. pylori-infected outpatients with endoscopically proven peptic ulcer diseases or&#xD;
        gastritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous H. pylori-eradication therapy&#xD;
&#xD;
          2. ingestion of antibiotics, bismuth, or PPIs within the prior 4 weeks&#xD;
&#xD;
          3. patients with allergic history to the medications used&#xD;
&#xD;
          4. patients with previous gastric surgery&#xD;
&#xD;
          5. the coexistence of serious concomitant illness (for example, decompensated liver&#xD;
             cirrhosis, uremia)&#xD;
&#xD;
          6. pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-Chen Tai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Chang Gung Memorial Hospital,Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei-Chen Tai, MD</last_name>
    <phone>886-0975056026</phone>
    <email>luketai1019@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seng-Kee Chuah, MD</last_name>
    <phone>886-975056007</phone>
    <email>sengkeechuah@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83300</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Chen Tai, MD</last_name>
      <phone>886-0975056026</phone>
      <email>luketai1019@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Seng-Kee Chuah, MD</last_name>
      <phone>886-975056007</phone>
      <email>sengkeechuah@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 28, 2021</last_update_submitted>
  <last_update_submitted_qc>November 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Wei-Chen Tai M.D.</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori eradication</keyword>
  <keyword>Hybrid therapy</keyword>
  <keyword>High dose dual proton pump inhibitor and Amoxicillin therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

